Hossein Kamali

Dr. Hossein Kamali


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2022 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
FRFarzad Rahmani
Farzad Rahmani
RARabi Atabaki
Rabi Atabaki
SBSetareh Behrouzi
Setareh Behrouzi
FMFarnoosh Mohamadpour
Farnoosh Mohamadpour
HKHossein Kamali
Hossein Kamali

6 July 2023 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
FRFarzad Rahmani
Farzad Rahmani
SNSaghi Naderpour
Saghi Naderpour
BNBehnam Ghorbani Nejad
Behnam Ghorbani Nejad
MRMilad Rahimzadegan
Milad Rahimzadegan
ZEZivar Nejad Ebrahimi
Zivar Nejad Ebrahimi
RNRahim Nosrati
Rahim Nosrati

6 September 2024 in Heliyon
Verified
Journal Article
Open access
NRNadiyeh Rouhi
Nadiyeh Rouhi
ZCZahra Chakeri
Zahra Chakeri
BNBehnam Ghorbani Nejad
Behnam Ghorbani Nejad
MRMilad Rahimzadegan
Milad Rahimzadegan
MKMohammad Rafi Khezri
Mohammad Rafi Khezri
RNRahim Nosrati
Rahim Nosrati
Alzheimer's disease (AD) is characterized by progressive neurodegeneration, memory loss, and cognitive impairment leading to dementia and death. The blood-brain barrier (BBB) prevents the delivery of drugs into the brain, which can limit their therapeutic potential in the treatment of AD. Therefore, there is a need to develop new approaches to bypass the BBB for appropriate treatment of AD. Recently, focused ultrasound (FUS) has been shown to disrupt the BBB, allowing therapeutic agents to penetrate the brain. In addition, microbubbles (MBs) as lipophilic carriers can penetrate across the BBB and deliver the active drug into the brain tissue. Therefore, combined with FUS, the drug-encapsulated MBs can pass through the ultrasound-disrupted zone of the BBB and diffuse into the brain tissue. This review provides clear and concise statements on the recent advances of the various FUS-mediated MBs-based carriers developed for delivering AD-related drugs. In addition, the sonogenetics-based FUS/MBs approaches for the treatment of AD are highlighted. The future perspectives and challenges of ultrasound-based MBs drug delivery in AD are then discussed.

7 March 2024 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MKMalihe Karimi
Malihe Karimi
MAMojtaba Abrishami
Mojtaba Abrishami
MFMehdi Farzadnia
Mehdi Farzadnia
HKHossein Kamali
Hossein Kamali
BMBizhan Malaekeh-Nikouei
Bizhan Malaekeh-Nikouei

17 December 2022 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
FHFarzin Hadizadeh
Farzin Hadizadeh
EKElham Khodaverdi
Elham Khodaverdi
FOFatemeh Oroojalian
Fatemeh Oroojalian
PRPouria Rahmanian-Devin
Pouria Rahmanian-Devin
SHS. Hassan M. Hashemi
S. Hassan M. Hashemi
HKHossein Kamali
Hossein Kamali
In this study, the Supercritical Carbon Dioxide (scCO2) gas foaming procedure was used in the preparation of scaffolds containing the model drug dexamethasone (DXMT). The method used did not include an organic solvent thus making it a safe method. The ring-opening polymerization of PCL-PEG-PCL (PCEC) triblock was conducted using an organocatalyst [1,8 diazabicyclo [5.4.0] undec-7-ene (DBU)]. After mixing 5.0 g of DXMT with 50.0 g of PCEC, hydraulic pressure was applied to compress the mixed powder into disc-like tablets. The tablet-like scaffold of the triblock containing DXMT was inserted into a scCO2 gas-foaming device. The peak porosity percentage of the synthesized triblock was found to be 55.58 %. Pressure, temperature, soaking time and the time required to depressurize were recorded as 198 bar, 50 °C, 2.0 h, and 28 min respectively. After treatment with scCO2, the scaffolds experienced an almost full release of DXMT in vitro after 30 days (83.74 ± 1.54 % vs 52.24 ± 2.03 % before scCO2 treatment). In conclusion, the results proved that the scCO2 gas foaming procedure could be employed for constructing modifiable PCEC scaffolds with plausible porosity and structural and morphological features which can manipulate drug release.

1 December 2021 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
VMVahideh Mohammadzadeh
Vahideh Mohammadzadeh
MZMohammad Reza Zirak
Mohammad Reza Zirak
SKSeyedeh Maryam Hosseini Khah
Seyedeh Maryam Hosseini Khah
HKHossein Kamali
Hossein Kamali
MJMahmoud Reza Jaafari
Mahmoud Reza Jaafari